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Sustained Release of Erythropoietin
Using Biodegradable Gelatin Hydrogel
Microspheres Persistently Improves Lower Leg Ischemia
Longhu Li, MD,* Hideshi Okada, MD,* Genzou Takemura, MD,* Masayasu Esaki, MD,*
Hiroyuki Kobayashi, MD,* Hiromitsu Kanamori, MD,* Itta Kawamura, MD,*
Rumi Maruyama, PHD,* Takako Fujiwara, MD,† Hisayoshi Fujiwara, MD,*
Yasuhiko Tabata, PHD,‡ Shinya Minatoguchi, MD*
Gifu and Kyoto, Japan
Objectives We hypothesized that erythropoietin (EPO)-immersed gelatin hydrogel microspheres (GHM) injected into isch-
emic legs might continuously release a small amount of EPO to locally stimulate angiogenesis without unfavor-
able systemic effects.
Background EPO is a potent angiogenic factor, but its use for relieving ischemic organs is limited because of the untoward
systemic erythrogenic effect and its short half-life in plasma.
Methods The right femoral arteries of BALB/c mice were ligated. Recombinant human EPO (5,000 IU/kg)-immersed GHM
was injected into the right hind limb muscles (n  12); the control groups included a saline-injected group
(n  12), an EPO-injected group (n  8), and an empty GHM-injected group (n  8).
Results Eight weeks later, improvement of blood perfusion to the ischemic limb was significantly augmented in the EPO-GHM
group compared with any of the control groups. There was no increase in the hemoglobin level, nor was there any
increase in endothelial progenitor cells. However, capillary and arteriolar densities were significantly increased in this
group. Although the treatment did not affect the levels of vascular endothelial growth factor or interleukin-1 beta, it
up-regulated the EPO receptor and matrix metalloproteinase-2 and activated the downstream signaling of Akt and
also endothelial nitric oxide synthase in ischemic limbs, which might have been associated with the evident angio-
genic and arteriogenic effects in the present system.
Conclusions The present drug delivery system is suggested to have potential as a novel noninvasive therapy for ischemic pe-
ripheral artery disease. (J Am Coll Cardiol 2009;53:2378–88) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.056d
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rhe incidence of arteriosclerosis obliterans (ASO), the most
ommon cause of peripheral artery disease, is estimated to
e 500 to 1,000 cases per million people per year (1), and the
umber of patients with ASO has increased recently because
f the growing prevalence of diabetes mellitus and hyper-
ension, the aging population, and tobacco consumption.
reatment of ASO includes anticoagulants and antiplatelet
rom the *Division of Cardiology, Gifu University Graduate School of Medicine,
ifu, Japan; †Department of Food Science, Kyoto Women’s University, Kyoto,
apan; and the ‡Department of Biomaterials, Institute for Frontier Medical Sciences,
yoto University, Kyoto, Japan. Supported in part by a post-doctoral fellowship for
oreign researchers (to Dr. Li) from the Japan Society for the Promotion of
cience, and grant-in-aid for scientific research No. 19-07207 from the Ministry
f Education, Science and Culture of Japan. Drs. Li and Okada contributed
qually to this work.e
Manuscript received December 19, 2008; revised manuscript received February 18,
009, accepted February 24, 2009.rugs, percutaneous transluminal angioplasty, and bypass
urgery. However, the prognosis for patients with ASO still
emains poor, and amputation of the lower extremities is
ften required (2). Enhancement of angiogenesis and col-
ateral arterial growth is a promising new therapeutic strat-
gy for ASO.
The hematogenous cytokine erythropoietin (EPO) is pro-
uced by the adult kidney and is indispensable for the prolif-
ration, survival, and differentiation of erythroid progenitor
ells (3). EPO has been found to be a potent angiogenic factor.
revious studies have shown that EPO, in vitro, enhances the
ifferentiation of endothelial cells into vascular structures (4).
urthermore, recent studies have suggested that EPO also
xerts an angiogenic activity in ischemia-induced injury in the
rain (5), retina (6), and heart (7). However, its use for
elieving ischemic organs is limited because of an untoward
rythrogenic effect (i.e., polycythemia) and its short half-life in
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June 23, 2009:2378–88 Erythropoietin Delivery System to the Ischemic Leghe plasma (i.e., 18.3 h after subcutaneous injection of 3,000 IU
PO in humans). We have developed an EPO-immersed
iodegradable gelatin hydrogel sheet that gradually releases
PO and finally disappears; the sheet, when attached on the
nfarct area of the heart, was found to improve cardiac function
nd remodeling at the chronic stage (8). We hypothesized
hat EPO-immersed gelatin hydrogels injected into isch-
mic limbs might continuously release a small amount of
PO to locally stimulate angiogenesis without unfavorable
ystemic effects. To test this idea, in the present study we
ade gelatin hydrogel microspheres (GHM) (mean diam-
ter, 30 m) from the sheet (9), examined the effect of
PO-immersed GHM (EPO-GHM) on lower leg ischemia,
nd investigated the specific mechanisms of the observed
ffects.
ethods
reparation of EPO-GHM. The gelatin hydrogel sheet
as made as previously described (8). The sheet was broken
nto microspheres with a mean diameter of 30m by a method
reviously reported (9). Recombinant human EPO (Chugai
harmaceutical Co., Tokyo, Japan) incorporation into acidic
nd basic gelatin microspheres was carried out by allowing the
reeze-dried microspheres to swell with an aqueous solution of
PO. Briefly, 15 l of EPO solution (140 IU EPO) were
ixed with 2 mg of dried glutaraldehyde-cross-linked micro-
pheres; they were then left at 4°C for 6 h to incorporate the
PO-GHM. The microspheres were diluted with 100 l
aline just before use. Similarly, EPO-free, empty GHMs were
repared using saline without EPO. We reported that EPO
as continuously released from the gelatin hydrogel sheet for at
east 14 days (8), and it is known that protein release rate from
elatin hydrogels is independent of the form of gelatin hydro-
els (sheet or microsphere) (9). Thus, EPO-GHM is expected
o release EPO for at least 14 days.
perative procedure and treatments. Male 9-week-old
ALB/c mice were purchased from Japan SLC (Shizuoka,
apan). This study was approved by the respective Institutional
nimal Research Committees. Under sufficient anesthesia
ith sodium pentobarbital and local fur removal with depila-
ory cream, hind limb ischemia was induced by entire ligation
f the right femoral artery just below the inguinal ligament. In
ham-operated mice (n  8), the suture was passed through
ut not tied.
After ligation, mice were randomly assigned to 4 groups:
roup S (saline-treated control group), which received intra-
uscular injection of saline (n  12); Group EPO, which
eceived an intramuscular injection of EPO at a dose of 5,000
U/kg into the hind limb (n  8); Group GHM, which
ntramuscularly received a saline-immersed (empty) GHM
n  8); and Group EPO-GHM, which intramuscularly
eceived EPO (5,000 IU/kg)-immersed GHM (n  12).
eagents were intramuscularly injected at 10 points in the hind
imb. The dose of EPO was in a tightly controlled range of the
nown dosages for organ protection (10–13). Eight weeks bfter surgery, all of the mice were
acrificed with an overdose of pen-
obarbital. Muscular specimens
ere then subjected to immuno-
istochemical and molecular bio-
ogical analysis.
To evaluate the role of endo-
helial progenitor cells (EPCs) in
he present model, some of the
ice were treated in the same
anner, and on day 3 or at week
after surgery, the mice of each
roup (n  6) were sacrificed.
eripheral blood was collected for
uorescence-activated cell sorter
FACS) analysis.
aser Doppler imaging. The
lood flow ratio of the ischemic
imb (right)/nonischemic limb
left) was measured using a laser
oppler perfusion imager (Moor
nstruments, Devon, United
ingdom). Mice were monitored
y serial scanning of surface blood flow of the hind limbs
efore ligation, just after ligation, and on day 3 and at weeks
, 2, 4, 6, and 8 after ligation.
emoglobin measurement. Hemoglobin was evaluated by
emoCue Hb 201 (HemoCue, A¨ngelholm, Sweden)
sing blood from the tail vein before and during treatment.
ononuclear cell isolation and flow cytometry analysis.
eripheral blood mononuclear cells were isolated from each
roup (n  6 each) using density gradient centrifugation
ith Ficoll (Immuno-Biological Laboratories, Minneapolis,
innesota). Light density mononuclear cells were harvested
nd washed twice with phosphate-buffered saline. EPCs
ere defined by positive staining for CD34 and Flk-1
CD34/Flk-1), CD34 and CD133 (CD34/CD133),
r CD34 and Sca-1 (CD34/Sca-1). Antibodies against
D34 and Sca-1 were purchased from BD Bioscience (San
ose, California) and those against CD133 and Flk-1 from
Bioscience (San Diego, California). Antimouse fluorescein
(6)-isothiocyanate-conjugated CD4 and antirat immuno-
lobulin G2a antibodies served as controls (BD Pharmingen
BD Bioscience]). After incubation, erythrocytes were lysed
sing the FACS lysing solution. Cells were then washed using
hosphate buffered saline and analyzed with FACS Caliber
Becton Dickinson, Franklin Lakes, New Jersey). Each anal-
sis included 100,000 events. The positive control blood
ample (n 6) was prepared from mice that were administered
ranulocyte colony-stimulating factor via subcutaneous injec-
ion at the dose of 100 g/kg once daily for 5 continuous days.
mmunohistochemical analysis. Four-m-thick deparaf-
nized sections from the lower calf muscles were incubated
ith primary antibodies against CD31, alpha-smooth muscle
ctin (1A4), muscle actin (HHF35), Ki-67, and von Wille-
Abbreviations
and Acronyms
ASO  arteriosclerosis
obliterans
eNOS  endothelial nitric
oxide synthase
EPC  endothelial
progenitor cell
EPO  erythropoietin
EPO-GHM  erythropoietin-
immersed gelatin hydrogel
microspheres
ERK  extracellular signal-
regulated protein kinase
FACS  fluorescence-
activated cell sorter
HPF  high-power field
STAT  signal transducer
and activator of
transcription
TUNEL  in situ nick
end-labelingrand factor (all from Dako Japan). An ABC kit (Vector,
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Erythropoietin Delivery System to the Ischemic Leg June 23, 2009:2378–88urlingame, California) was then used for immunostaining,
ith diaminobenzidine HCl serving as the chromogen. Quan-
itative assessments, including the number or area of the
mmunopositive cells, were made in 20 randomly chosen
igh-power fields (400) using a multipurpose color image
rocessor. For immunofluorescence, Alexa Fluor 568 and 488
Molecular Probes, Invitrogen, Carlsbad, California) were the
econdary antibodies. Nuclei were counterstained with hema-
oxylin or Hoechst 33342. Digital images of specimens with
mmunofluorescence, which were captured using a laser-
onfocal microscope system (LSM510, Zeiss, Oberkochen,
ermany), were used for morphometric and quantitative
nalyses using Adobe Photoshop 7.0 software (Adobe Systems
nc., San Jose, California).
In situ nick end-labeling (TUNEL) assay was performed
sing an ApopTag kit (Intergene, Purchase, New York)
ccording to the supplier’s instructions.
estern blotting. Lysates from hind limb muscle tissue
omogenates harvested 8 weeks after surgery or cultured cells
ere used for Western blot analysis. Proteins were separated
nd transferred to membranes by standard protocols, after
hich they were probed with antibodies against the EPO
eceptor (EPOR, M-20, Santa Cruz, California). Downstream
ediators of EPO receptor signaling were assessed using
ntibodies against Akt, the phosphorylated-Akt (p-Akt), ex-
racellular signal-regulated protein kinase (ERK), p-ERK, and
ignal transducer and activator of transcription 3 (STAT3),
-STAT3, STAT5, and p-STAT5 (all from Cell Signaling,
anvers, Massachusetts). Expression and activation of en-
othelial nitric oxide synthase (eNOS) were assessed with
ntibodies against eNOS (Cell Signaling) and p-eNOS (BD
harmingen). Matrix metalloproteinase-2 and -9 were as-
essed with antibodies against matrix metalloproteinase-2
Daiichi Fine Chemical, Toyama, Japan) and matrix
etalloproteinase-9 (Santa Cruz Biotechnology, Santa
ruz, California). Three to 5 right hind limb muscles from
ach group were subjected to blotting. The blots were
isualized by means of chemiluminescence (Amersham, GE
ealthcare Biosciences, Uppsala, Sweden), and the signals
ere quantified by densitometry. Alpha-tubulin (Santa
ruz) or -actin (Sigma, St. Louis, Missouri) served as the
oading control.
nzyme-linked immunosorbent assay. Both hind limb
uscles from each group (n  3 to 5) were harvested 8 weeks
fter surgery and total proteins were extracted by lysing the cells
n lysis buffer (50 mM Tris/HCl, pH 7.5/10 mM ethylenedi-
minetetraacetic acid/100 mM NaCl/0.1% Triton X-100).
he levels of mouse vascular endothelial growth factor and
ouse interleukin-1beta were assayed with enzyme-linked
mmunosorbent assay (R&D Systems, Minneapolis,
innesota).
n vitro cell proliferation assay. Endothelial cells and
ascular smooth muscle cells of human aorta origin (Cas-
ade Biologics Inc., Invitrogen, Portland, Oregon) were
lated into 96-well plates and cultured for 24 h, after which
U/ml EPO and/or 2 mol/l wortmannin, an Akt inhib-tor, was added and the cultures were continued for an
dditional 24 h. Then 10 ml of Cell Counting Kit-8 (Wako,
ichmond, Virginia) was added to each well, and the cells
ere incubated for another 4 h. The accumulated formazan
as then solubilized, and the absorbance at 450 nm was
easured.
tatistical analysis. Values are shown as mean  standard
rror of the mean. Statistical analysis was performed by analysis
f variance followed by the Newman-Keuls multiple compar-
son test. For statistical analysis of blood flow ratio in Figure 1
nd of EPC mobilization in Figure 4, we used a repeated-
easures analysis of variance. Values of p  0.05 were
onsidered significant.
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Figure 1 Blood Perfusion of the Ischemic Hind Limb
(A) Laser Doppler blood perfusion. (B) Blood perfusion in ischemic hind limbs
was measured before, just after, on day 3, and at weeks 1, 2, 4, 6, and 8
after right femoral artery ligation. Results are expressed as the ratio of the
right (ischemic) to left (nonischemic) limb perfusion. *p  0.05, EPO or EPO-
GHM versus the other groups; #p  0.05, EPO or EPO-GHM versus saline and
GHM. EPO  erythropoietin; EPO-GHM  erythropoietin-immersed gelatin hydro-
gel microspheres; GHM  gelatin hydrogel microspheres.
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lood perfusion of the ischemic hind limb. Laser Doppler
maging showed that blood flow in the ischemic hind limb was
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Figure 2 Ischemic Limb Histology in Mice After Ligation of the
(A) Photomicrographs of immunohistochemical CD31, alpha-smooth muscle actin
or 8 weeks after ligation. Scale bars: 20 m. (B) Graphs showing the morphomet
groups. E  erythropoietin; EG  erythropoietin-immersed gelatin hydrogel microsp
abbreviations as in Figure 1.ecreased equally in all groups immediately after femoral artery aigation. Although blood perfusion progressively recovered
rom day 3 after ischemia, improvement of blood perfusion to
he ischemic limb 8 weeks after ligation was significantly
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ontrol groups (Fig. 1). In Group EPO, blood flow recovery
ncreased at weeks 1, 2, and 4, but returned to the control
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Figure 3 Effects on the Proliferation or Apoptosis of Vessels in
(A) Graphs showing the proliferating or apoptotic index of vessels at 8 weeks afte
groups. (B) Confocal micrographs of the ischemic limb specimen taken from th
(red fluorescence) with Ki-67 (green fluorescence). Scale bars: 20 m. TUNEL
Figures 1 and 2.roup level thereafter. veovascularization in lower ischemic hind limbs. Immu-
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June 23, 2009:2378–88 Erythropoietin Delivery System to the Ischemic Legared with the sham group (Fig. 2). Vessel formation was
ndeed enhanced in the EPO-alone treated group at 2 weeks
fter surgery, when the blood flow in the ischemic limb was
emporally improved, without, however, an accompanying
ncrease of arteriolar density. In contrast, the EPO-GHM
roup displayed enhanced capillary (106  7.0/high-power
eld [HPF]) and arteriolar density (12.5  1.1/HPF) at 8
eeks (Fig. 2). Immunohistochemical staining for muscle actin
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Figure 4 EPC Mobilization in Response to Ischemia and Treatm
(A) Evaluation of CD34/Flk-1cell mobilization 7 days after treatments using FAC
and CD34/Sca-1cells in total peripheral blood mononuclear cells (PBMC) on da
tor cell; FACS  fluorescence-activated cell sorter; G-CSF  granulocyte colony-stimevealed that ischemia significantly induced muscle degenera- Kion and loss, which was not altered in any of the treatment
roups, although the CD31-positive vessel to muscle cell ratio
as augmented in Group EPO-GHM (Fig. 2). In nonisch-
mic limbs, there was no significant difference in the vessel
ensity, arteriole density, or HHF35-positive muscle area.
hese were similar to the levels in the sham group, indicating
o influence of any treatment on nonischemic limbs.
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Graphs showing the percentages of CD34/Flk-1cells, CD34/CD133cells,
7 after surgery. *p  0.05 versus the sham group. EPC  endothelial progeni-
g factor; other abbreviations as in Figure 1.133
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.09/HPF) compared with any of the control groups (Fig. 3).
n the other hand, although femoral artery ligation increased
UNEL-positive vessels, there was no difference in the inci-
ence among the ischemic groups (Fig. 3). In nonischemic
imbs, there was no significant difference in Ki-67 or TUNEL
ositivity among the groups. Neither Ki-67–positive nor
UNEL-positive myocytes were noted in any group.
PCmobilization in response to ischemia and treatment.
lthough the hemoglobin level of mice was significantly
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Figure 5 Western Analysis for EPO Receptor Expression and Do
(A to C) Graphs showing morphometric data. *p  0.05 versus the sham group;
receptor; ERK  extracellular signal-regulated protein kinase; STAT  signal transncreased 2 weeks after a single injection of EPO (15.7  a.20 g/dl vs. 14.4  0.32 g/dl at baseline, p  0.05),
here was no significant change in the other groups,
ncluding Group EPO-GHM. Because EPO has also
een reported to be a potent stimulus of EPC mobiliza-
ion (15), we examined the effect of EPO on EPCs
haracterized by CD34/Flk-1, CD34/CD133, or
D34/Sca-1 expression. We found no significant
ifference in the number of EPCs in peripheral blood
ononuclear cells between groups on days 3 or 7 after
urgery (Fig. 4). Methodologic validation of our FACS
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June 23, 2009:2378–88 Erythropoietin Delivery System to the Ischemic LegPCs in the peripheral blood of mice that received
ranulocyte colony-stimulating factor. It is thus sug-
ested that EPCs are not involved in neovascularization
n the present model.
xpression of EPO receptor and its downstream media-
ors in the ischemic hind limb. Western blot analysis
howed that EPO receptor expression in ischemic limbs was
ignificantly enhanced by EPO-GHM treatment (Fig. 5),
Figure 6 Assessment of Angiogenic Factors in Ischemic Limbs
(A) Muscular levels of vascular endothelial growth factor (VEGF) or interleukin-1 be
(B) Western analysis for the expression of endothelial nitric oxide synthase (eNOS
show the morphometric data. *p  0.05 versus the sham group; #p  0.05 versulthough no difference was noted in nonischemic limbs wmong the groups. Western blot analysis showed that
mong downstream mediators of EPO receptor, ERK,
TAT3, and STAT5, or their phosphorylated forms, were
ot related to the beneficial effects of EPO-GHM treat-
ent, although the expression of ERK or its activation
phosphorylation) was significantly increased in ischemic
imbs compared with sham (Fig. 5). On the other hand, Akt
nd p-Akt were markedly up-regulated in groups treated
1) (pg/mg protein) determined by enzyme-linked immunosorbent assay.
OS, and matrix metalloproteinase (MMP)-2, and -9 in ischemic limbs. Graphs
other control groups. Abbreviations as in Figure 2.ta (IL-
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orms, were similar to those of the sham-operated group,
ith no significant differences.
xpression of angiogenic factors in the ischemic hind
imb. Vascular endothelial growth factor is known as a key
egulator of physiological and pathological angiogenesis
16). Interleukin-1 beta is reported to play an important role
n neovascularization of ischemic limbs (17). Of the cyto-
ines tested (Fig. 6A), no significant difference in expression
f vascular endothelial growth factor in the right hind limb
as found with or without ligation between groups. How-
ver, expression of interleukin-1beta was markedly up-
egulated in ischemic limbs compared with sham, and it was
ot influenced by any treatments. In nonischemic legs, expres-
ion levels of vascular endothelial growth factor and
nterleukin-1 beta were similar to those of the sham-operated
roup, with no significant difference among the groups.
A recent study suggested that EPO also up-regulates
xpression of p-eNOS in carotid artery injury (18). Western
lot analysis showed that p-eNOS was markedly up-
egulated in groups treated with EPO-GHM, indicating
ctivation of eNOS (Fig. 6B). Taking this finding together
ith up-regulation of Akt and p-Akt, it is implied that the
kt/eNOS pathway might be substantially involved in the
eovascularization induced by EPO-GHM. Akt signaling
s linked to activation of matrix metalloproteinase-2 and -9,
hich can promote angiogenesis (19). Our Western blot-
ing revealed that matrix metalloproteinase-2, but not ma-
rix metalloproteinase-9, was significantly up-regulated only
n the ischemic legs of Group EPO-GHM mice (Fig. 6B).
n nonischemic legs, there was no difference in matrix
etalloproteinase-2 or -9 expression among the groups.
n vitro effects of EPO on endothelial cells and vascular
mooth muscle cells. EPO increased cell proliferation of
ultured endothelial cells, accompanying an increase in
ctivity of Akt and eNOS; all of these were abrogated by
ortmannin. In cultured vascular smooth muscle cells, EPO
ffected neither cell proliferation nor Akt activity (eNOS
ctivity is absent in the basal condition) (Fig. 7).
iscussion
PO-GHM and neovascularization in local ischemia.
he present study demonstrated that a significant miti-
ation of lower leg ischemia persisted for up to 8 weeks
ith the treatment with EPO-GHM, implying a novel
oninvasive therapy application in ischemic peripheral
rtery disease. Blood flow in the ischemic legs was indeed
ncreased by a single injection of EPO, but the effect
eased at 8 weeks, in contrast to the EPO-GHM
pplication.
In general, blood vessels form in various ways: vasculo-
enesis refers to the formation of blood vessels by EPCs and
ngiogenesis refers to sprouting from the pre-existing ves-
els (20). They may be subsequently stabilized by mural cells
arteriogenesis), where monocyte activation plays a majorole (21). Vasculogenesis as the result of EPC activity was
nlikely to be involved in neovascularization in the present
odel, since EPC mobilization was not altered by the
pplied EPO-GHM formulation (Fig. 4A), similar to a lack
f erythrocytosis after treatment. Pathological findings of
he present study show that EPO-GHM significantly
nhanced angiogenesis in ischemic limbs without an eryth-
ogenic effect. Furthermore, alpha-smooth muscle actin-
ositive vessels (arterioles) were also increased in the EPO-
HM group. In contrast, treatment with EPO alone
nduced a temporal increase in capillaries but not arterioles,
uggesting that the vessels regressed because of a lack of
aturation in the EPO-alone group. These findings suggest
hat persistence of the blood flow improvement by EPO-
HM is attributable to the formation of mature vessels
arterioles) and that long-lasting local stimulation by EPO
B
A
β
Figure 7
Effect of EPO and Akt Inhibitor
Wortmannin on Cell Proliferation of Cultured
Endothelial Cells and Vascular Smooth Muscle Cells
(A) Western analysis for the expression of p-Akt and p-eNOS. (B) Cell prolifera-
tion assay. *p  0.05 versus the untreated group; #p  0.05 versus the EPO-
treated group. EC  endothelial cell; eNOS  endothelial nitric oxide synthase;
VSMC  vascular smooth muscle cell; other abbreviations as in Figure 1.
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ew vessels.
We also observed that EPO-GHM treatment, under
onditions in which significant improvement of blood per-
usion was achieved, did not restore the muscle loss caused
y ischemia. It is unclear at present why significant blood
ow improvement did not restore or augment muscle tissue
reas of the ischemic limb. However, muscle regeneration is
complex process and may consume time periods of 60 to
0 days or longer (22,23).
olecular mechanisms underlying the neovasculariza-
ion exerted by EPO-GHM. Our Western blot analysis
howed that EPO receptor expression in ischemic limbs was
ignificantly enhanced by EPO-GHM treatment. This is
onsistent with an earlier report (24), in which both EPO
nd hypoxia were shown to be required to up-regulate EPO
eceptor. In the heart and brain, EPO receptor signaling can
timulate the PI3K/Akt, Jak/STAT, and ERK/MAPK
ignaling pathways (7,8,10,25). EPO was recently reported
o up-regulate the expression of p-eNOS in the carotid
rtery (18). Our findings suggest that altered signaling via
kt and eNOS, but not ERK, STAT3, or STAT5, is
nvolved in the neovascularization induced by EPO-GHM.
ur in vitro finding confirmed that EPO-mediated prolif-
ration of ECs depends on Akt activation. Activated Akt
ubsequently phosphorylates and activates eNOS, leading to
he production of NO (26). NO is not only a vasodilator but
lso is known to mediate angiogenesis (27). Another recent
tudy using eNOS knockout mice showed that endogenous
NOS promotes angiogenesis and arteriogenesis, but has
o effect in endothelial progenitor cell recruitment (28).
upatt et al. (29) showed that transfection of a constitu-
ively active eNOS-mutant also enhances collateral forma-
ion (macro-arteriogenesis). These data suggest that the
kt/eNOS pathway activated by EPO is associated with cell
roliferation of endothelial cells, which, in turn, induces
roliferation of vascular smooth muscle cells to mature
essels. Taken together, we therefore suggest that EPO-
HM exerts not only angiogenesis but also arteriogenesis
ia the Akt/eNOS signaling pathway.
In addition, up-regulation of matrix metalloproteinase-2
as noted in ischemic limbs treated with EPO-GHM.
atrix metalloproteinase-2 activation, whose expression
s up-regulated via Akt signaling (30), is known to
romote angiogenesis through degradation of various
xtracellular matrix proteins (31). A recent study showed
oor angiogenesis in the ischemic legs of matrix
etalloproteinase-2 knockout mice (32). Although the
ctivity remains to be confirmed because the antibodies
or matrix metalloproteinase-2 used here detect only the
roform, our findings suggest treatment with EPO-
HM modulates matrix metalloproteinase-2 activation
n the ischemic limbs, which could promote angiogenesis.
iscrepancies with previous studies. Previous studies in-
icated that vasculogenesis occurs through circulating bone
arrow-derived EPCs (33,34). EPO has also been reportedo be a potent stimulus of EPC mobilization (15). In the
resent study, we failed to detect increased EPCs in the
eripheral blood of the experimental group, suggesting little
elevance of EPCs to angiogenesis by EPO-GHM. More-
ver, we also noted no increase of peripheral EPCs in the
ther control groups. Although these observations appear to
onflict with those of previous studies (15,35–37), it should
e noted that there is a difference in the experimental model
mouse strain and operative procedure) between the previ-
us studies and ours. Not unlike humans, BALB/c mice, as
sed in this study, show a recovery of ischemic limb
erfusion of about 50% after femoral artery ligation. In
ontrast, the often used C57BL/6 mice are capable of
ntirely restoring blood flow in the ischemic limb between 2
nd 4 weeks after femoral artery ligation (32,38), severely
imiting the detection of long-term treatment effects. More-
ver, EPC contribution to blood flow recovery in C57BL/6
ice was obtained after a more invasive procedure of
omplete femoral artery excision or coagulation (15,35–37)
as used, which might release more proangiogenic signals
o the bone marrow, in turn mobilizing EPCs more effi-
iently. Furthermore, administration protocols of EPO were
ifferent: a single injection of 5,000 U/kg EPO in our study
ersus multiple-time injection of 1,000 IU/kg EPO 6 times
n C57BL/6 mice (15) or 5,000 IU EPO 8 times in humans
39). Frequent stimulation by EPO as well as the total
mount of EPO may be important for inducing EPCs into
eripheral blood.
linical implications. The present study reports promis-
ng results of a new method of therapeutic angiogenesis for
reatment of limb ischemia with a slow-release system of
PO using biodegradable gelatin hydrogels. At present,
oth EPO and gelatin hydrogels are already in use in the
linical setting, with safety clearly established, so the unfa-
orable systemic effect of EPO is avoidable with this
ethod. We believe that this therapy is safer, less invasive,
nd more promising compared with previous therapeutic
ngiogenesis and is readily applicable to patients suffering
rom peripheral artery disease.
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